arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Barinthus Biotherapeutics plc.

BRNS

$0.60 0.00 (0.00%) at close

6 Visible periods

27 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Barinthus Biotherapeutics plc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $24.3M

Dividend Yield —

Revenue Growth N/M

Op. Margin None

ROIC -94.8% ↘

FCF / Share $-1.18 ↘

Trailing P/E —

Price / Book 0.3x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 3, 2026.

6-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

↓ -100.0% —

Net Income Profit after all expenses

$-66.43M

↓ -8.8% —

Operating Margin Operating profit as % of sales

-454.1%

↓ -4923.1% —

FCF / Share Free cash flow per share

$-1.18

↓ -56.3% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue Growth YoY (%)	N/M	1766.5% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+21981%)	-98.2% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1328%)	16580.2% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+207153%)	-94.4% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1281%)	—
EPS Growth YoY (%)	-5.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	18.8% Good Good Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	12.5% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	—
Net Income Growth YoY (%)	-8.8% Weak Weak Year-over-year change in net income	16.7% Good Good Year-over-year change in net income	N/M	N/M	-187.3% Weak Weak Year-over-year change in net income	—
FCF Growth YoY (%)	-56.3% Weak ↓ Weak Declining Year-over-year change in free cash flow	48.3% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-165.8% Weak ↓ Weak Declining Year-over-year change in free cash flow	57.6% Excellent Excellent Year-over-year change in free cash flow	9.1% Fair Fair Year-over-year change in free cash flow	—
Revenue CAGR 3Y (%)	—	282.3% Excellent Excellent Compound annual revenue growth over 3 years	-45.0% Weak Weak Compound annual revenue growth over 3 years	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Operating Margin (%) (%)	—	-454.1% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3127%)	—	-9.0% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-160%)	—	-415.8% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2872%)
Effective Tax Rate (%) (%)	0.3% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	4.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-526.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	-408.0% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3500%)	—	11.9% Fair Fair Net income as a percentage of revenue Optimal: > 15% vs Sector: At sector avg	—	-367.3% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3161%)
FCF Margin (%) (%)	—	-199.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-46.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	-234.8% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%
FCF / Net Income (x)	0.72x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.49x Weak ↑ Weak Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	-3.85x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.64x Weak Weak Free cash flow relative to reported net income Optimal: > 1x

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Return on Invested Capital (%)	-94.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-52.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-43.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-10.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-17.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-71.9% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-39.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-1.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-39.6% Weak Weak Operating profit relative to total assets Optimal: > 10%
Return on Common Equity (%) (%)	-89.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-697%)	-47.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-413%)	-39.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-362%)	2.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-85%)	-20.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-234%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Interest Coverage (x)	—	—	-2996.93x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-212.68x Weak ↓ Weak Declining Operating income divided by interest expense Optimal: > 5x	-16.95x Weak Weak Operating income divided by interest expense Optimal: > 5x	-5.57x Weak Weak Operating income divided by interest expense Optimal: > 5x
Net Debt (USD)	$-70.46M	$-110.66M	$-142.09M	$-194.38M	$-214.05M	$-43.27M

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Revenue per Share (USD)	$0.00	$0.38	$0.02	$1.20	$0.01	$0.61
Basic EPS, GAAP (USD)	$-1.64	$-1.55	$-1.91	$0.14	$-1.96	$-2.24
Free Cash Flow per Share (USD)	$-1.18	$-0.76	$-1.47	$-0.55	$-1.30	$-1.43
Book Value per Share (USD)	$1.82	$3.23	$4.83	$6.45	$6.78	—
Tangible Book Value per Share (USD)	$1.47	$2.69	$3.87	$5.37	$5.59	—
Basic Weighted Avg Shares (shares)	40.53M	39.35M	38.39M	37.25M	25.89M	7.90M

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Working Capital (USD)	$67.77M	$110.08M	$144.31M	$200.80M	$215.61M	$40.26M
Total Equity (USD)	$74.21M	$130.03M	$186.78M	$242.90M	$252.12M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$14.97M	$802.00K	$44.70M	$268.00K	$4.82M
Depreciation Expense (USD)	$5.84M	$5.80M	$5.43M	$4.32M	$602.00K	$208.00K
Net Income, GAAP (USD)	$-66.43M	$-61.07M	$-73.35M	$5.34M	$-50.87M	$-17.71M
Operating Cash Flow (USD)	$-47.98M	$-28.94M	$-50.92M	$-14.43M	$-32.58M	$-11.03M

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 25 quarters

Barinthus Biotherapeutics plc.

Analytical Summary

6-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare BRNS with peers